- Results Presented at Leading Global MS Congress -
JERUSALEM--(BUSINESS WIRE)--Sep 8, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009. Featured presentations and abstracts will include new data onCOPAXONE®, the global leading treatment for relapsing-remitting multiple sclerosis (RRMS), as well as on the company's compounds in advanced development.
"For nearly two decades Teva has supported the MS community and our ongoing commitment to research and development will continue to provide effective MS treatments while maintaining safety as well as contribute to a greater understanding of the disease,” said Moshe Manor, Teva's Group Vice President, Global Branded Products. “Our dedication has not only brought forth the world's leading MS treatment, COPAXONE®, but we are looking forward to continually support the MS community through our evolving pipeline, led by oral laquinimod.”
>> Continue Reading from drugs.com
A similar version of this article was posted to this blog on September 8th, but do to a bad link I had to suspend that posting and then post again.. - Sorry for any inconvenience this may have caused.
============================================
0 comments:
Post a Comment